| |
Cases vs. Controls
|
Cases vs. EUR
†
|
|---|
|
Variant
|
OR (95% CI
#
), unadjusted model
|
OR (95% CI
#
), adjusted model*
|
OR (95% CI
#
), unadjusted model
|
|---|
|
c.5682G > C
|
0.30 (0.09-0.85)
|
0.05 (0.00 - 1.00)
|
0.43 (0.16-0.94)
|
|
c.5814A > G
|
0.16 (0.03-0.63)
|
0.01 (0.00 - 0.27)
|
0.32 (0.08-0.91)
|
|
c.5844A > G
|
0.16 (0.03-0.63)
|
0.01 (0.00 - 0.27)
|
0.29 (0.07-0.80)
|
- *Adjusted jointly for age, gender, treatment duration and daily dose per ideal bodyweight.
- †Patients treated with CQ and affected with toxic maculopathy were compared to data from 267 European individuals obtained from the 1000 Genomes Project.
- #Confidence intervals.
